회사 개요
Novartis AG operates as a leading pharmaceutical entity that researches, develops, manufactures, distributes, and markets medicines across Switzerland and international markets, with a primary focus on therapeutic areas such as heart failure treatment using agents like Entresto. The company functions within the Healthcare sector, specifically classified under the Drug Manufacturers - General industry, which denotes its role in creating essential prescription medications for global patient care. This Swiss-based enterprise commands a substantial market capitalization of $291.89B and generates an annual revenue of $56.67B based on trailing twelve-month data, while employing a workforce of 75,267 individuals globally. The magnitude of its market cap combined with its multi-billion dollar revenue stream positions Novartis as a large-cap blue-chip stock, indicating a mature organization with established market share and significant operational scale in the competitive global pharmaceutical landscape.
재무 건전성
Novartis reported a trailing twelve-month revenue of $56.67B alongside a net income of $13.98B and an EBITDA of $23.47B, revealing a cost structure where operating expenses and taxes consume approximately 75.3% of top-line sales before reaching the bottom line. The company generated free cash flow of $12.12B, a figure that underscores its robust financial flexibility to fund research and development initiatives, return capital to shareholders, or acquire strategic assets without immediate reliance on external financing. The company maintains a gross margin of 76.0%, reflecting the high-value nature of pharmaceutical products, an operating margin of 27.8% that demonstrates efficient control over general and administrative costs, and a profit margin of 24.7% that signifies strong overall profitability relative to revenue. In terms of solvency, Novartis holds $11.53B in cash against total debt of $35.46B, resulting in a debt-to-equity ratio of 76.17, which suggests a leveraged balance sheet typical of capital-intensive pharmaceutical firms rather than a conservative cash-rich position. Liquidity is further assessed by a current ratio of 1.12, indicating that the company possesses slightly more current assets than current liabilities to meet its short-term obligations. Management effectiveness is highlighted by a return on equity of 30.8% and a return on assets of 11.1%, metrics that demonstrate the ability to generate significant profits from shareholders' investments and total asset base respectively.
밸류에이션 평가
The stock trades with a trailing P/E ratio of 21.15 and a forward P/E of 15.38, implying that the market expects earnings growth in the future that would compress the current valuation multiple from the historical average. The price-to-book ratio stands at 6.26, suggesting that the market values the company at a significant premium over its book value, likely due to the intangible value of its intellectual property portfolio and brand equity. Alternative valuation metrics include a price-to-sales ratio of 5.15 and an EV/EBITDA of 13.33, which provide context on how the company is priced relative to its sales volume and operational earnings power compared to peers. Over the past year, the stock has fluctuated between a 52-week low of $97.72 and a 52-week high of $170.46, providing a clear trading range for analyzing recent price action. With a beta of 0.52, the stock exhibits lower volatility than the broader market, meaning its price movements tend to be less sensitive to general market fluctuations compared to high-beta technology or growth stocks.
Growth & Income
Revenue growth for the trailing twelve months was recorded at 2.2%, while earnings growth declined by 11.6% year-over-year, indicating that profitability is currently contracting faster than sales expansion, possibly due to pricing pressures or increased costs in research and development. As a consistent dividend payer, Novartis offers a dividend yield of 3.1% with a payout ratio of 55.9%, a level that appears sustainable given the company's strong cash flow generation and moderate debt load relative to equity. The current decline in earnings growth relative to revenue suggests that the company is facing headwinds in converting sales into net profit, which could impact the sustainability of the dividend if operational efficiency does not improve. Overall, the growth and income profile presents a mature pharmaceutical stock with modest sales growth, declining earnings, but a resilient dividend yield supported by substantial free cash flow.